Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PRME · as of Mar 31, 2025
Ownership Breakdown
127
Institutional Holders
▼ 6 vs Q4
$120.42M
Total Inst. Value
▼ $67.58M vs Q4
180.62M
Shares Outstanding
freeFloat 32.76%
60.39M
13F Shares Held
▼ 3.95M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PRME largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ALPHABET INC. biological products, (no diagnostic substances) | 15.06M | 11.51% | 11.51% | $29.97B | May 2, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.31M | 3.29% | 3.29% | $8.57B | May 2, 2025 | ▼ 218.6K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 4.14M | 3.17% | 3.17% | $8.24B | May 14, 2025 | ▲ 165.3K |
FMR LLC biological products, (no diagnostic substances) | 3.75M | 2.86% | 2.86% | $7.46B | May 12, 2025 | ▼ 54.8K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.64M | 2.78% | 2.78% | $7.25B | May 9, 2025 | ▼ 14.0K |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 3.10M | 2.36% | 2.36% | $6.16B | May 7, 2025 | ▼ 2.06M |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 2.93M | 2.24% | 2.24% | $5.82B | May 7, 2025 | ▼ 164.2K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 2.93M | 2.24% | 2.24% | $5.82B | Apr 25, 2025 | ▼ 164.2K |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 2.07M | 1.58% | 1.58% | $4.13B | May 15, 2025 | — held |
MWG MANAGEMENT LTD. biological products, (no diagnostic substances) | 1.79M | 1.37% | 1.37% | $3.57B | May 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
17
Increased
+1.52M shares4
New Positions
first time holders17
Decreased
−3.47M shares0
Sold Out
fully exitedNet shares change (top 50)
1.95M
+1.52M / −3.47M
Net new holders
+4
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PRME insider trading · insider activity
Source: SEC Form 4
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Makhni Svetlana Ni Chief Financial Officer | Apr 16, 2026 | Award | 800,000 | $3.67 | $2.94M | 800.0K | Form 4 ↗ |
Reine Allan Chief Executive Officer | Feb 26, 2026 | Award | 1,300,000 | $4.38 | $5.69M | 1.30M | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Feb 23, 2026 | Award | 375,000 | $3.34 | $1.25M | 375.0K | Form 4 ↗ |
Alenson Carman See Remarks | Feb 23, 2026 | Award | 140,000 | $3.34 | $467.6K | 140.0K | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | Award | 180,995 | $4.04 | $731.2K | 181.0K | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | D-Return | 180,995 | $12.30 | $2.23M | 0 | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | D-Return | 180,995 | $8.49 | $1.54M | 0 | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | Award | 45,000 | $4.04 | $181.8K | 45.0K | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | Award | 39,062 | $4.04 | $157.8K | 39.1K | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | D-Return | 45,000 | $7.68 | $345.6K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Prime Medicine, Inc. (PRME) is primarily owned by institutional investors, who hold approximately 33.4% of total shares outstanding. Company insiders own approximately 67.24%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Prime Medicine, Inc. is ALPHABET INC., holding approximately 15.06 million shares — equal to 11.51% of outstanding shares — as of March 31, 2025.
A total of 127 institutional investors currently hold PRME stock, with a combined institutional value of approximately $120,417,954 as of the most recent 13F filing period.
Frequently asked questions
PRME ownershipPrime Medicine, Inc. (PRME) is primarily owned by institutional investors, who hold approximately 33.4% of shares. The largest shareholder is ALPHABET INC. with a 11.51% stake. Company insiders hold 67.24%. Data sourced from SEC Form 13F as of March 31, 2025.